Zoetis: Deep Value Narrative Clashes with Structural Growth Concerns

What happened

Zoetis reported Q4 2025 results with 3% revenue and 5.7% EPS growth, as highlighted in a recent Seeking Alpha article that frames this as resilient performance and points to osteoarthritis drug launches Portela and Lenivia as 2026 catalysts. However, DeepValue's analysis exposes underlying weaknesses, including a 12% year-on-year decline in U.S. osteoarthritis monoclonal antibody sales due to safety concerns and persistent livestock revenue drops. These headwinds forced a revenue guidance cut in late 2025, contributing to a stock price decline of about 28% from early 2025 highs, yet the shares still trade at a premium ~20.9x P/E multiple. The company's growth has decelerated from mid-teens to mid-single digits, with management acknowledging OA mAb disappointments and slowing companion-animal momentum offsetting strong parasiticide and dermatology franchises. Thus, while the article portrays a deep-value opportunity, the reality is a business grappling with product-specific risks and a subdued growth trajectory that challenges near-term upside.

Implication

The Seeking Alpha article's optimistic take on Zoetis overlooks critical structural issues detailed in DeepValue's report, such as declining U.S. osteoarthritis monoclonal antibody sales and ongoing livestock weakness that have already prompted guidance cuts. OA mAb challenges, including safety perceptions around Librela, are not easily remedied by new launches like Portela and Lenivia, requiring sustained vet confidence and regulatory clarity before meaningful recovery. Livestock revenue remains a drag due to divestitures and cyclical pressures, undermining overall growth and offsetting strengths in companion-animal segments like Simparica and dermatology. With organic growth slowing to mid-single digits and a dividend increase reduced to 6% for 2026, the high-teens compounder narrative is fading, justifying a premium multiple only if OA stabilization occurs soon. Therefore, investors are better off waiting for clearer signs of OA turnaround or a more attractive entry price below $110, as recommended in DeepValue's 'WAIT' rating, rather than chasing the article's value persistence theme.

Thesis delta

The Seeking Alpha article reinforces Zoetis's operational resilience and pipeline potential, but DeepValue's critical analysis confirms that OA mAb safety concerns and livestock softness pose significant near-term growth barriers. This blend underscores no material shift in the investment thesis, which remains a 'WAIT' with a need for OA recovery or price correction to improve risk-reward.